Company Description
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company.
It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design α-helical peptides through computational and ML tools.
The company’s IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs.
It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology.
The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026.
Decoy Therapeutics Inc. is based in Houston, Texas.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Frederick Pierce |
Contact Details
Address: 2450 Holcombe Blvd, Suite X Houston, Texas 77021 United States | |
| Phone | 713 913 5608 |
| Website | decoytx.com |
Stock Details
| Ticker Symbol | DCOY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001615219 |
| CUSIP Number | 79400X602 |
| ISIN Number | US79400X6022 |
Key Executives
| Name | Position |
|---|---|
| Frederick E. Pierce II | Chief Executive Officer and Director |
| Mark J. Rosenblum CPA | Executive Vice President of Finance and Chief Financial Officer |
| Dr. Barbara Hibner Ph.D. | Chief Scientific Officer |
| Peter K. Marschel M.B.A., M.S. | Chief Business Officer |
| Dr. Nadeem Q. Mirza M.D., M.P.H. | Senior Vice President of Clinical Development |